Brief: Orthocell Signs Striate Global License And Manufacturing Agreement
27/06/2022 11:22
June 27 (Reuters) - Orthocell Ltd OCC.AX :
* SIGNS STRIATE GLOBAL LICENSE AND MANUFACTURING AGREEMENT
* SIGNS A STRIATE+TM GLOBAL EXCLUSIVE LICENCE AND
MANUFACTURING
AGREEMENT WITH BIOHORIZONS IMPLANT SYSTEMS
* BIOHORIZONS AGREES TO PAY ORTHOCELL A$23.1 MILLION
Source text for Eikon: ID:nASXc5vV2f
Further company coverage: OCC.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Orthocell
See all newsBrief: Orthocell Reports September Quarter Revenue Of A$3.6 Million
Australia's Orthocell rises as flagship product records first Thailand sales
Brief: Orthocell Says QTRLY A$3.2 Million Revenue Achieved
Australia's Orthocell set for best week since November 2024 on US DoD approval for key product
Brief: Orthocell's First Surgical Use Of Remplir In US Department Of Defense